Patents by Inventor Stephen Trokel

Stephen Trokel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10940042
    Abstract: The presently disclosed subject matter provides techniques for inducing collagen cross-linking in human tissue, such as cartilage or cornea, without using a photosensitizer (e.g., riboflavin), by inducing ionization of the water contained in the tissue to produce free radicals that induce chemical cross-linking in the human tissue. In an embodiment, a femtosecond laser operates at sufficiently low laser pulse energy to avoid optical breakdown of tissue. In an embodiment, the femtosecond laser operates in the infrared frequency range.
    Type: Grant
    Filed: October 23, 2016
    Date of Patent: March 9, 2021
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Sinisa Vukelic, Stephen Trokel
  • Publication number: 20180221201
    Abstract: The presently disclosed subject matter provides techniques for inducing collagen cross-linking in human tissue, such as cartilage or cornea, without using a photosensitizer (e.g., riboflavin), by inducing ionization of the water contained in the tissue to produce free radicals that induce chemical cross-linking in the human tissue. In an embodiment, a femtosecond laser operates at sufficiently low laser pulse energy to avoid optical breakdown of tissue. In an embodiment, the femtosecond laser operates in the infrared frequency range.
    Type: Application
    Filed: October 23, 2016
    Publication date: August 9, 2018
    Applicant: The Trustees of Columbia University in the City of New York
    Inventors: Sinisa VUKELIC, Stephen TROKEL
  • Publication number: 20180193188
    Abstract: The presently disclosed subject matter provides techniques for inducing collagen cross-linking in human tissue, such as cartilage or cornea, without using a photosensitizer (e.g., riboflavin), by inducing ionization of the water contained in the tissue to produce free radicals that induce chemical cross-linking in the human tissue. In an embodiment, a femtosecond laser operates at sufficiently low laser pulse energy to avoid optical breakdown of tissue. In an embodiment, the femtosecond laser operates in the infrared frequency range.
    Type: Application
    Filed: February 9, 2018
    Publication date: July 12, 2018
    Applicant: The Trustees of Columbia University in the City of New York
    Inventors: Sinisa VUKELIC, Stephen TROKEL
  • Patent number: 9125856
    Abstract: Disclosed are compounds and related methods useful for cross-linking collagen and stabilizing collagenous tissues using formaldehyde-donating compounds or nitrogen oxide-containing compounds such as ?-Nitro Alcohols. Also disclosed are compounds and related methods for modulating the rate or degree of collagen cross-linking using nitrogen oxide-containing compounds such as ?-Nitro Alcohols. The formaldehyde-donating, nitrogen oxide-containing and/or ?-Nitro Alcohol compounds disclosed are capable of stabilizing collagenous tissues such as the corneal and scleral tissues and are useful in the treatment or prevention of diseases such as alterations in corneal curvature, keratoconus, keratectasia, progressive myopia and glaucoma.
    Type: Grant
    Filed: September 20, 2012
    Date of Patent: September 8, 2015
    Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
    Inventors: David Choohyun Paik, Stephen Trokel
  • Patent number: 8580789
    Abstract: Provided herein are methods of protecting all or a portion of the optic nerve fiber layer within the optic nerve/lamina cribrosa (ONLC) complex in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of an agent that results in crosslinking of collagen in the indiviudal's peripapillary sclera, thereby stiffening the individual's peripapillary sclera and protecting all or a portion of the optic nerve fiber layer within the ONLC of the individual. In a particular embodiment, the invention is directed to methods of treating glaucoma in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of an agent that results in crosslinking of collagen in the indiviudal's peripapillary sclera, thereby stiffening the individual's peripapillary sclera and treating the glaucoma in the individual.
    Type: Grant
    Filed: April 2, 2008
    Date of Patent: November 12, 2013
    Assignees: The Cleveland Clinic Foundation
    Inventors: Ronald R. Krueger, William J. Dupps, Stephen Trokel, Ivey Thornton
  • Publication number: 20100273749
    Abstract: The subject application provides an aqueous composition suitable for use as an artificial tear solution comprising one or more lipids produced by an enzyme of the diacylglycerol acyltransferase 2 (DGAT2) family and/or the acyl-CoA cholesterol acytransferase (ACAT) family. This invention also provides related methods.
    Type: Application
    Filed: December 28, 2006
    Publication date: October 28, 2010
    Inventors: Stephen L. Sturley, Aaron Turkish, Stephen Trokel
  • Patent number: 5735843
    Abstract: An argon-fluoride excimer laser or other laser source capable of generating far-ultraviolet radiation at 193 nm is pulsed with energy densities of greater than 20 mj per cm.sup.2 at a repetition rate up to 25 pulses per second to direct its radiation through a mask and onto corneal tissue, or other biological matter, to form an ablation therein of predetermined configuration and depth by a process of ablative photodecomposition. The masks are formed with a slit, circular, crescent or other openings of widths between 30 and 800 microns, and may even be formed to provide a graded intensity center to edge. The mask is reflective or composed of or faced with an organic polymer to prevent heat build-up.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: April 7, 1998
    Assignee: VISX, Incorporated
    Inventor: Stephen Trokel
  • Patent number: 5711762
    Abstract: An argon-fluoride excimer laser or other laser source capable of generating far-ultraviolet radiation at 193 nm is pulsed with energy densities of greater than 20 mj per cm.sup.2 at a repetition rate up to 25 pulses per second to direct its radiation through a mask and onto corneal tissue, or other biological matter, to form an ablation therein of predetermined configuration and depth by a process of ablative photodecomposition. The masks are formed with a slit, circular, crescent or other openings of widths between 30 and 800 microns, and may even be formed to provide a graded intensity center to edge. The mask is reflective or composed of or faced with an organic polymer to prevent heat build-up.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: January 27, 1998
    Assignee: Visx, Incorporated
    Inventor: Stephen Trokel
  • Patent number: 4988163
    Abstract: A low energy laser system for surgical purposes, in particular, ophthalmic surgery, comprises a source of pulsed laser energy. Er:YAG lasers having a wavelength of 3 microns are preferred. Optical fibers which are responsive to the laser energy deliver amounts of the laser energy to selected body tissue sufficient to perform delicate surgical procedures without adverse biological or chemical interaction with the tissue. In particular, a compound fiber assembly is preferred for delivery of laser energy having a wavelength above 2 microns which compound fiber comprises an elongated fiber body comprised of fluoride based glass, a surgical optical fiber tip of a hard, moderately transparent mineral, such as quartz or sapphire, and an element for coupling the optical fiber tip to the fluoride glass body.
    Type: Grant
    Filed: August 17, 1989
    Date of Patent: January 29, 1991
    Assignee: Quantronix Corp.
    Inventors: Martin G. Cohen, William I. Kern, Stephen Trokel